Modifiers of risk of hereditary breast and ovarian cancer

Nature Reviews Cancer

Volumn 2, Issue 2, 2002, Pages 113-123

  Narod, Steven A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT; TAMOXIFEN; BRCA1 PROTEIN; BRCA2 PROTEIN;

ALLELISM; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; FAMILIAL CANCER; GENE MUTATION; GENETIC RISK; HORMONE SUBSTITUTION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ALLELE; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; OVARY TUMOR; PENETRANCE; RISK FACTOR;

ALLELES; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OVARIAN NEOPLASMS; PENETRANCE; RISK FACTORS;

EID: 0036488497     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc726     Document Type: Review

References (77)

1. Risch, H. A. et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68, 700-710 (2001). Describes the BRCA1/BRCA2 mutation frequency and associated risks of cancer in a large, population-based series of women with invasive ovarian cancer.
2. Nuemann, H. P. H. et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N. Engl. J. Med. 329, 1531-1538 (1993).
3. Wohllk, N. et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 81, 3740-3745 (1996).
4. Aziz, S. et al. A genetic epidemiology study of carcinoma of the fallopian tube. Gynecol. Oncol. 80, 341-345 (2001).
5. Frank, T. S. et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J. Clin. Oncol. 16, 2417-2425 (1998).
6. Struewing, J. P. et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336, 1401-1408 (1997).
7. Tonin, P. et al. Frequency of recurrent BRCA1 and BRCA2 mutations in 222 Ashkenazi Jewish breast cancer families. Nature Med. 2, 1179-1183 (1966).
8. Thorlacius, S. et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am. J. Hum. Genet. 60, 1079-1084 (1997).
9. Gorski, B. et al. BRCA1 founder mutations in Poland. Am. J. Hum. Genet. 66, 1963-1968 (2000).
10. Wacholder, S. et al. The kin-cohort study for estimating penetrance. Am. J. Epidemiol. 148, 623-630 (1998).
11. Warner, E. et al. Prevalence of BRCA mutations in an unselected population of Ashkenazi Jewish women with ovarian cancer. J. Natl. Cancer Inst. 91, 1241-1247 (1999).
12. Moslehi, R. et al. BRCA1 and BRCA2 mutation analysis of 230 Ashkenazi Jewish women with ovarian cancer. Am. J. Hum. Genet 55, 1259-1272 (2000).
13. Ford, D. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet. 62, 676-689 (1998). Uses a panel of 237 families with a high incidence of breast cancer to estimate the cumulative risks of breast and ovarian cancer in carriers of BRCA1 and BRCA2 mutations.
14. Easton, D. F. et al. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am. J. Hum. Genet. 56, 265-271 (1995).
15. Meijers-Heijboer, H. et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345, 159-164 (2001).
16. Mazoyer, S. et al. A polymorphic stop codon in BRCA2. Nature Genet. 14, 253-254 (1996).
17. Thompson, D. & Easton, D. Variation in cancer risks by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet. 66, 410-419 (2001). Uses a panel of 164 families with BRCA2 mutations to estimate the risks of breast and ovarian cancer by position of mutation in the BRCA2 gene.
18. Gayther, S. A. et al Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet. 11, 428-433 (1995). Uses a panel of 60 families with BRCA1 mutations to correlate the position of the mutation within the BRCA1 gene with the ratio of breast and ovarian cancers in the family.
19. Fodor, F. L. et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am. J. Hum. Genet. 63, 45-51 (1998).
20. Sinilnikova, O. et al. Polymorphisms in BRCA1 and 17β -hydroxysteroid dehydrogenase 2 (EDH17B2) genes as modifiers of ovarian cancer risk in carriers of BRCA1 germline mutations. Am. J. Hum. Genet. 69, S150 (2001).
21. Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J. & Malkowicz, S. B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90, 1225-1229 (1998).
22. Jernstrom, H. et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol. Genet. Metab. 72, 144-154 (2001).
23. Chamberlain, N. L. et al. The length and location of CAG trinucleotide repeat in the androgen receptor N-terminal domain affect transactivation activities. Nucleic Acids Res. 2, 3181-3186 (1994).
24. Giguere, Y. et al. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res. 61, 5869-5874 (2001).
25. Spurdle, A. B. et al. Androgen receptor exon 1 CAG repeat length and breastcancer in women before age 40 years. J. Natl Cancer Inst. 91, 961-966 (1999).
26. Dunning, A. M. et al. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis 20, 2131-2135 (1999).
27. Park, J. J. et al. Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor. Cancer Res. 60, 5946-5949 (2000).
28. Rebbeck, T. R. et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am. J. Hum. Genet. 64, 1371-1377 (1999). A case-control study of BRCA1-mutation carriers, comparing the specific alleles of the androgen-receptor polymorphism and breast cancer risk. In addition, reference 24 shows this effect in the non-carrier breast cancer population.
29. Dagan, E. et al. Androgen receptor CAG repeat lengths in Jewish Israeli women who are BRCA1/2 mutation carriers: relevance to breast/ovarian cancer morbidity. Am. J. Hum Genet. 69, 376 (2001).
30. Levine, D. A. & Boyd, J. The androgen receptor and genetic susceptiblity to ovarian cancer: results from a case series. Cancer Res. 61, 908-911 (2001).
31. Helztsouer, K. J. et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. J. Am. Med. Assoc. 274, 1926-1930 (1995).
32. Yoshida-Komiy, H. et al. The steroid receptor coactivator SRC (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc. Natl Acad. Sci. USA 97, 6379-6384 (2000).
33. Anzick, S. L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968 (1997).
34. Rebbeck, T. R. et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 61, 5420-5424 (2001). Shows that the risk of breast cancer in BRCA1-mutation carriers is modified by the NCOA3 polymorphism.
35. Patel, M. S. et al. Alleles of the estrogen receptor-α gene and an estrogen receptor co-transcriptional activator gene, amplified in breast cancer-1 (AIB-1) are associated with quantitative calcaneal ultrasound. J. Bone Mineral Res. 15, 2231-2239 (2000).
36. Baumann, P. & West, S. C. Role of the human RAD51 protein in homologous recombination and double-stranded break repair. Trends Biochem. Sci. 23, 247-251 (1998).
37. Wang, W. et al. A single nuclectide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 10, 421-574 (2001).
38. Levy-Lehad, E. et al. A single nuclectide polymorphisms in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc. Natl Acad. Sci. USA 98, 3232-3236 (2001).
39. Krontiris, T. et al. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N. Engl. J. Med. 329, 517-523 (1993). Reviews the evidence that the VNTR polymorphism, downstream of HRAS1, modifies the risk of cancer at several sites.
40. Phelan, C. M. et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genet. 12; 309-311 (1996). This study of BRCA1-mutation carriers with and without ovarian cancer shows that rare alleles of the VNTR polymorphism, downstream of HRAS1, increases the risk of ovarian cancer.
41. Narod, S. A. et al. Increasing incidence of breast cancer in family with BRCA1 mutation. Lancet 341, 1101-1102 (1993).
42. Vogel, F. Genetics of retinoblastoma. Hum. Genet. 52, 1-54 (1979).
43. Neuhausen, S. L. et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am. J. Hum. Genet. 62, 1381-1388 (1998).
44. Narod, S. A. et al. Risk modifiers in carriers of BRCA1 mutations. Int. J. Cancer 64, 394-398 (1995).
45. Rebbeck, T. R. et al. Reduction in breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl Cancer Inst. 91, 1475-1479 (1999). A historical cohort study that found a significant reduction in breast cancer risk in BRCA1-mutation carriers following oophorectomy.
46. Eisen, A. et al. Reduction in breast cancer risk following bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet. 67, 58 (2000).
47. Beral, V. & Reeves, G. Childbearing, oral contraceptive use and breast cancer. Lancet 341, 1102 (1993).
48. Russo, J. et al. Influence of age and panty on the development of the human breast. Breast Cancer Res. Treat. 23, 211-218 (1992).
49. Johannson, O., Loman, N., Borg, A. & Olsson, H. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet 352, 1359-1360 (1998).
50. Jernstrom, H. et al. Pregnancy increases the risk of early onset breast cancer in BRCA1 and BRCA2 carriers. Lancet 354, 1846-1850 (1999). A case-control study that found that pregnancy significantly increased the risk of breast cancer up to age 40 in women with BRCA1 mutations.
51. Jernstrom, H. et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 carriers. Am. J. Hum. Genet. 69, S418 (2001).
52. Ursin, G. et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res. 57, 3678-3681 (1997).
53. Grabick, D. M. et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. J. Am. Med. Assoc. 284, 1791-1798 (2000).
54. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative re-analysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347, 1713-1727 (1996).
55. Narod, S. A. et al. Oral contraceptives and the risk of hereditary ovarian cancer. N. Engl. J. Med. 339, 424-428 (1998). An international case-control study that showed that the use of oral contraceptives was associated with a significant decrease in the risk of ovarian cancer among BRCA1-mutation carriers.
56. Narod, S. A. et al. Tubal ligation and risk of ovarian cancer carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 357, 1467-1470 (2001). An international case-control study that showed that tubal ligation was associated with a decrease in the risk of ovarian cancer. Reference 60 is a large prospective study (of nurses) that showed that tubal ligation dramatically decreased the risk of subsequent ovarian cancer.
57. Narod, S. A., Sun, P. & Risch, H. Ovarian cancer, oral contraceptives, and BRCA mutations. N. Engl. J. Med. 345, 1706-1707 (2001).
58. Modan, B. et al. Panty, oral contraceptives, and the risk of ovarian cancer among carriers and non-carriers of a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345, 235-240 (2001).
59. Hankinson, S. E. et al. Tubal ligation, hysterectomy and the risk of ovarian cancer. J. Am. Med. Assoc. 270, 2813-2818 (1993).
60. Piek, J. M. J. et al. Tubal ligation and risk of ovarian cancer. Lancet 358, 844 (2001).
61. Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project Pi study. J. Natl Cancer Inst. 90, 1371-1388 (1998). A large randomized trial of tamoxifen use in healthy women showed that tamoxifen use reduced the incidence of new cases of breast cancer by approximately 50%.
62. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351, 1451-1467 (1998).
63. King, M.-C. et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. J. Am. Med. Assoc. 286, 2251-2256 (2001). This describes tamoxifen use in the subset of 19 BRCA1- or BRCA2-mutation carriers in the cohort study in reference 61 who developed breast cancer.
64. Narod, S. A. et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 carriers. Lancet 356, 1876-1881 (2000). A large, international case-control study, which shows that tamoxifen use decreases the risk of contralateral breast cancer by approximately 50% in carriers of BRCA1 or BRCA2 mutations.
65. Steinberg, K. et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. J. Am. Med. Assoc. 265, 1985-1990 (1991).
66. Powles, T. et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352, 98-101 (1998).
67. Veronesi, U. et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352, 93-97 (1998).
68. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl Cancer Inst. 91, 1310-1316 (1999).
69. Fan, S. et al. BRCA1 inhibition of estrogen receptor signalling in transfected cells. Science 284, 1354-1356 (1999).
70. Zheng, L. et al. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc. Natl Acad. Sci. USA 98, 9587-9592 (2001).
71. Annab, L. A. et al. Increased survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line. Breast Cancer Res. 2, 139-148 (2000).
72. Hoeijmakers, J. H. Genomic maintenance mechanisms for preventing cancer. Nature 441, 366-367 (2001).
73. Orelli, B. J. & Bishop, D. K. BRCA2 and homologous recombination. Breast Cancer Res. 3, 294-298 (2001).
74. Combs, G. F. & Gray, W. P. Chemopreventive agents: selenium. Pharmacol. Ther. 79, 179-192 (1998).
75. Kavanagh, K. T. et al. Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J. Cell. Biochem. 82, 387-398 (2001).
76. Nakachi, K. et al. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 13, 49-54 (2000).
77. Bradlow, H. L. et al. Multifunctional aspects of the action of indole-3-carbinol as an antitumour agent. Cancer Prevention: novel nutrient and pharmaceutical developments. Ann. NY Acad. Sci. 889, 204-213 (1999).